Healthcare Equipment and Supplies
Company Overview of Entellus Medical, Inc.
Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation; and FinESS sinus dilation system, a solution for treatment of the maxillary sinus drainage pathway. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red tra...
3600 Holly Lane North
Plymouth, MN 55447
Founded in 2006
Key Executives for Entellus Medical, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $93.0K
Total Annual Compensation: $458.9K
Vice President of Clinical, Regulatory & Quality and Compliance Officer
Total Annual Compensation: $240.0K
Vice President of Sales
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.
Entellus Medical, Inc. Key Developments
Entellus Medical, Inc. Appoints John K. Bakewell as a Class I Director
Jul 9 15
On July 7, 2015, the board of directors of Entellus Medical, Inc. increased the size of the Board from six to seven directors and appointed John K. Bakewell, 54, to fill the resulting vacancy. In addition, the Board appointed Mr. Bakewell to the audit committee of the Board. Mr. Bakewell will serve on the Board as a Class I director for a term expiring at the company's 2016 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Bakewell has been the chief financial officer of Lantheus Holdings, Inc. since July 2014.
Entellus Medical, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 04:40 PM
May 26 15
Entellus Medical, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 04:40 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.
Entellus Medical, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter of 2015 and Revises Earnings Guidance for the Full Year of 2015
May 7 15
Entellus Medical, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $13,502,000 against $10,175,000 a year ago. Loss from operations was $3,450,000 against $2,119,000 a year ago. Net loss was $4,348,000 or $0.35 per diluted share against $2,535,000 or $1.80 per diluted share a year ago. The growth in revenue was primarily attributable to an increase of approximately $3.2 million in sales of the XprESS family of products.
The company estimates that second quarter 2015 revenue will range from approximately $14.8 million to $15.3 million, which would represent growth of approximately 18% to 22% versus the second quarter of 2014. The company expects that gross margin for the second quarter of 2015 will range from 77.5% to 78.5% compared to 78.3% in the second quarter of 2014. Second quarter operating expenses are expected to be in the range of $14.3 million to $15.3 million, with the increase primarily due to sales and marketing expenses related to the expansion of the U.S. sales organization, and from general and administrative expenses associated with the expense of operating as a public company. Second quarter net loss is estimated to range from approximately $2.8 million to $4.3 million, or an estimated net loss of $0.15 to $0.23 per share. The estimated net loss for the second quarter includes estimated non-cash stock-based compensation of $0.7 million to $0.8 million. The number of weighted average shares outstanding used to calculate estimated earnings per share for the second quarter is currently expected to range from approximately 18.7 million to 18.8 million.
The company continues to expect full year 2015 revenue will be in a range of $58.5 million to $61.0 million, representing growth of 20% to 25% annually and that gross margin will be in a range of 77% to 78% for 2015. The company expects operating expenses to be in a range of $59 million to $62 million, including estimated charges for stock-based compensation expenses of $2.5 million to $2.7 million. This compares to the company’s previous operating expense expectation for 2015 of $60 million to $63 million. Full year 2015 net loss is now expected to be in a range of $14.0 million to $19.0 million, or a net loss of $0.80 to $1.10 per share. This compares to the company’s previous expectations for net loss in the range of $14.6 million to $20.0 million, or a net loss of $0.84 to $1.17 per share. This expected net loss per share assumes approximately 17.2 million to 17.4 million weighted average shares outstanding for the year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|